Ampio Pharmaceuticals Inc. [AMPE] moved down -0.11: Why It’s Important

Ampio Pharmaceuticals Inc. [AMEX: AMPE] slipped around 0.0 points on Monday, while shares priced at $0.09 at the close of the session, down -0.11%. The company report on August 3, 2022 that Ampio Pharmaceuticals Issues Letter to Stockholders.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), today released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.

Ampio Pharmaceuticals Inc. stock is now -83.56% down from its year-to-date (YTD) trading value. AMPE Stock saw the intraday high of $0.10 and lowest of $0.09 per share. The company’s 52-week high price is 1.83, which means current price is +16.25% above from all time high which was touched on 03/24/22.

Compared to the average trading volume of 7.72M shares, AMPE reached a trading volume of 7746387 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Ampio Pharmaceuticals Inc. [AMPE]?

ROTH Capital have made an estimate for Ampio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 19, 2019. While these analysts kept the previous recommendation, Aegis Capital raised their target price from $15 to $16. The new note on the price target was released on March 17, 2014, representing the official price target for Ampio Pharmaceuticals Inc. stock. Previously, the target price had yet another raise to $11, while Aegis Capital analysts kept a Buy rating on AMPE stock.

The Average True Range (ATR) for Ampio Pharmaceuticals Inc. is set at 0.01 The Price to Book ratio for the last quarter was 1.04, with the Price to Cash per share for the same quarter was set at 0.10.

How has AMPE stock performed recently?

Ampio Pharmaceuticals Inc. [AMPE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.54. With this latest performance, AMPE shares dropped by -9.90% in over the last four-week period, additionally sinking by -78.52% over the last 6 months – not to mention a drop of -93.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AMPE stock in for the last two-week period is set at 41.33, with the RSI for the last a single of trading hit 44.44, and the three-weeks RSI is set at 40.16 for Ampio Pharmaceuticals Inc. [AMPE]. The present Moving Average for the last 50 days of trading for this stock 0.1275, while it was recorded at 0.0928 for the last single week of trading, and 0.3670 for the last 200 days.

Ampio Pharmaceuticals Inc. [AMPE]: Deeper insight into the fundamentals

Return on Equity for this stock declined to -76.23, with Return on Assets sitting at -55.35.

Ampio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.80 and a Current Ratio set at 4.80.

Insider trade positions for Ampio Pharmaceuticals Inc. [AMPE]

There are presently around $3 million, or 13.70% of AMPE stock, in the hands of institutional investors. The top three institutional holders of AMPE stocks are: VANGUARD GROUP INC with ownership of 8,291,965, which is approximately -10.909% of the company’s market cap and around 7.64% of the total institutional ownership; BLACKROCK INC., holding 4,699,064 shares of the stock with an approximate value of $0.44 million in AMPE stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $0.19 million in AMPE stock with ownership of nearly 998.59% of the company’s market capitalization.

Positions in Ampio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 38 institutional holders increased their position in Ampio Pharmaceuticals Inc. [AMEX:AMPE] by around 5,944,366 shares. Additionally, 59 investors decreased positions by around 23,981,066 shares, while 51 investors held positions by with 537,263 shares. The mentioned changes placed institutional holdings at 30,462,695 shares, according to the latest SEC report filing. AMPE stock had 21 new institutional investments in for a total of 2,558,126 shares, while 31 institutional investors sold positions of 4,582,122 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here